Agendia

Agendia is a molecular diagnostic company. The company engages in the discovery, development, and commercialization of products to enhance the quality of life for cancer patients by providing healthcare professionals with critical information to enable personalized treatment. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology. Agendia is based in Amsterdam, the Netherlands and in Irvine, California.
History
Founded in 2003 as an offshoot of the Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital in Amsterdam, the company was established to pursue the commercialization of molecular diagnostics using DNA microarray technology for cancer diagnosis and drug development.
In 2004 Agendia launched the initial version of its breast cancer recurrence test in Europe. In 2006, MammaPrint® was selected by an international independent retrospective validation as the exclusive molecular diagnostic stratification tool for the MINDACT trial, featuring 6,600 patients at 109 institutions in nine European countries. In 2007, MammaPrint® became the first IVDMIA to obtain 510(k) clearance from the FDA, and after receipt of this regulatory clearance MammaPrint® became commercially available in the United States in 2008. As market awareness of the company’s products in the United States and Europe grew, Agendia introduced other breast cancer microarray tests, adding TargetPrint® in 2009 and also, in 2010, BluePrint™ and TheraPrint®. In 2011, Agendia began offering these tests as a comprehensive suite of products designed to help simplify complex breast cancer decisions. This suite of tests, now called [http://en. .org/wiki/Symphony_(Agendia) Symphony], provides clinically validated tests that can predict a patient’s responsiveness to adjuvant chemotherapy, helping to reduce unnecessary treatment and lower medical costs.
The company markets its tests in the United States, Europe, and internationally. It has collaborations with Roche, Novartis, Sanofi Aventis, Pfizer, Abbott, Amgen, and AstraZeneca. Agendia B.V. was incorporated in 2003 and is based in Amsterdam, the Netherlands and Irvine, California.
Products
Symphony, marketed by Agendia B.V., is a comprehensive suite of assays based on the analysis of hundreds of genes in any one patients’ breast cancer that yields biological information to aide physicians in deciding on an appropriate and individualized treatment approach for each patient.
See Also
[http://en. .org/wiki/Symphony_(Agendia) Symphony]

Main Menu